NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.74% | -15.82% | -8.22% | -16.22% | -14.05% |
| Total Other Revenue | 20.00% | 2.50% | 25.81% | 30.00% | 73.91% |
| Total Revenue | -6.65% | -15.76% | -8.14% | -16.13% | -13.90% |
| Cost of Revenue | -15.95% | -25.49% | -9.13% | -20.49% | -15.86% |
| Gross Profit | 0.56% | -8.11% | -7.37% | -12.41% | -12.32% |
| SG&A Expenses | -9.62% | -14.95% | -21.17% | -30.22% | -21.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.80% | -18.67% | -18.01% | -27.67% | -19.62% |
| Operating Income | 22.48% | 25.66% | 38.01% | 49.32% | 29.35% |
| Income Before Tax | 20.88% | 11.20% | 13.20% | 19.55% | -393.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.88% | 11.20% | 13.20% | 19.55% | -393.44% |
| Earnings from Discontinued Operations | 88.79% | 24.79% | -112.18% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.34% | 11.99% | 9.16% | 9.13% | -436.64% |
| EBIT | 22.48% | 25.66% | 38.01% | 49.32% | 29.35% |
| EBITDA | 21.70% | 23.51% | 35.71% | 47.16% | 27.36% |
| EPS Basic | 77.58% | 81.24% | 69.55% | 59.55% | -17.58% |
| Normalized Basic EPS | 85.18% | 71.48% | 62.91% | 35.98% | -31.80% |
| EPS Diluted | 77.58% | 81.24% | 69.55% | 59.55% | -17.58% |
| Normalized Diluted EPS | 85.18% | 71.48% | 62.91% | 35.98% | -31.80% |
| Average Basic Shares Outstanding | 1,610.26% | 779.92% | 460.42% | 161.12% | 102.16% |
| Average Diluted Shares Outstanding | 1,610.26% | 779.92% | 460.42% | 161.12% | 102.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
